Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 8/2015

01-11-2015 | Reply

Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country

Authors: F. S. Mennini, Andrea Marcellusi, J. M. Graf von der Schulenburg, A. Gray, P. Levy, P. Sciattella, M. Soro, G. Staffiero, J. Zeidler, A. Maggioni, R. E. Schmieder

Published in: The European Journal of Health Economics | Issue 8/2015

Login to get access

Excerpt

We wish to thank the Editor for giving us the opportunity to respond to the points raised by Prof. Afschin Gandjour, who has questioned the repeatability of the results based on the input data listed in the publication. Prof. Gandjour illustrates his point of view suggesting two steps to estimate the net cost of making one additional patient adherent to blood pressure (BP) treatment. …
Literature
1.
Mennini, F.S., et al.: Cost of poor adherence to anti-hypertensive therapy in five European countries. Eur. J. Health Econ. 16(1), 65–72 (2015)CrossRefPubMed
2.
Gandjour, A., Stock, S.: A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy 83(2–3), 257–267 (2007)CrossRefPubMed
3.
Montgomery, A.A., et al.: The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J. Hypertens. 21(9), 753–759 (2003)CrossRef
4.
Cramer, J.A., et al.: Medication compliance and persistence: terminology and definitions. Value Health 11(1), 44–47 (2008)CrossRefPubMed
Metadata
Title
Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country
Authors
F. S. Mennini
Andrea Marcellusi
J. M. Graf von der Schulenburg
A. Gray
P. Levy
P. Sciattella
M. Soro
G. Staffiero
J. Zeidler
A. Maggioni
R. E. Schmieder
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 8/2015
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-015-0712-y

Other articles of this Issue 8/2015

The European Journal of Health Economics 8/2015 Go to the issue

Original Paper

Economic evaluations of implantable cardioverter defibrillators: a systematic review

Commentary

Commentary to: Cost of poor adherence to anti-hypertensive therapy in five European countries

Original Paper

Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?

Editorial

Rationing of health care: is there an economic rationality to it?

Original Paper

Did the health of the Dutch population improve between 2001 and 2008? Investigating age- and gender-specific trends in quality of life

Original Paper

Relationship between global severity of patients with Alzheimer’s disease and costs of care in Spain; results from the co-dependence study in Spain